Lonza Group AG/€LONN
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Lonza Group AG
Lonza Group AG is a global company specializing in pharmaceutical, biotech, and nutrition sectors, headquartered in Basel, Switzerland. It provides integrated solutions for the creation of new drugs, ranging from active pharmaceutical ingredients (APIs) and drug formulation to drug delivery systems. The company serves a diverse clientele including pharmaceutical and biotech companies, offering contract development and manufacturing organization (CDMO) services. With operations in multiple countries, Lonza is strategically positioned to cater to global healthcare needs. Known for its extensive capabilities in cell and gene therapy, the organization leverages advanced technology platforms to support complex biopharmaceutical developments, enhancing its competitive edge in the industry.
Ticker
€LONN
Sector
Primary listing
XGAT
Employees
19,299
Headquarters
Basel, Switzerland
Website
Lonza Group AG Metrics
BasicAdvanced
€41B
52.92
€11.10
0.80
€4.28
0.36%
Price and volume
Market cap
€41B
Beta
0.8
52-week high
€655.43
52-week low
€499.00
Average daily volume
21K
Dividend rate
€4.28
Financial strength
Current ratio
1.456
Quick ratio
0.871
Long term debt to equity
48.398
Total debt to equity
53.181
Dividend payout ratio (TTM)
38.20%
Interest coverage (TTM)
7.52%
Profitability
EBITDA (TTM)
2,081.87
Gross margin (TTM)
36.47%
Net profit margin (TTM)
10.33%
Operating margin (TTM)
18.24%
Effective tax rate (TTM)
17.08%
Revenue per employee (TTM)
€396,030
Management effectiveness
Return on assets (TTM)
4.41%
Return on equity (TTM)
8.10%
Valuation
Price to earnings (TTM)
52.919
Price to revenue (TTM)
5.455
Price to book
4.45
Price to tangible book (TTM)
10.97
Price to free cash flow (TTM)
-103.172
Free cash flow yield (TTM)
-0.97%
Free cash flow per share (TTM)
-5.691
Dividend yield (TTM)
0.73%
Forward dividend yield
0.36%
Growth
Revenue change (TTM)
5.93%
Earnings per share change (TTM)
30.85%
3-year revenue growth (CAGR)
6.64%
10-year revenue growth (CAGR)
6.60%
3-year earnings per share growth (CAGR)
-37.21%
10-year earnings per share growth (CAGR)
10.07%
3-year dividend per share growth (CAGR)
10.06%
10-year dividend per share growth (CAGR)
4.81%
Bulls say / Bears say
Lonza’s CDMO business posted CHF 3.1 billion in H1 2025 sales, up 23.1% at constant exchange rates with a steady CORE EBITDA margin of 30.2%. As a result, the company upgraded its full-year CDMO sales growth outlook to 20–21% and its CORE EBITDA margin outlook to 30–31%. (Reuters)
The acquisition of the former Genentech Vacaville site remains on schedule to bring in around CHF 0.5 billion in sales in 2025, strengthening Lonza’s mammalian drug substance manufacturing and global diversification (Fierce Pharma).
New high-potency API and large-scale mammalian drug substance facilities in Visp began operating in Q1 and H1 2025, respectively, expanding Lonza’s manufacturing capacity for advanced and high-value biologic therapies (Lonza).
Specialized Modalities revenue dropped 9.2% at constant exchange rates in H1 2025, and its CORE EBITDA margin shrank to 17.3% from 23.4%, showing weaker performance in cell & gene and microbial segments (Investing.com).
Operational free cash flow decreased 36.1% to CHF 189 million before acquisitions and dropped 52.4% to CHF 141 million after acquisitions in H1 2025, raising concerns over cash generation as the company makes significant growth investments (MarketScreener).
Net debt rose to CHF 3.57 billion in H1 2025, pushing the net debt/CORE EBITDA ratio to 1.7x from 1.5x last year, which could limit financial flexibility amid heightened capex and acquisition spending (MarketScreener).
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lonza Group AG stock?
Lonza Group AG (LONN) has a market cap of €41B as of September 15, 2025.
What is the P/E ratio for Lonza Group AG stock?
The price to earnings (P/E) ratio for Lonza Group AG (LONN) stock is 52.92 as of September 15, 2025.
Does Lonza Group AG stock pay dividends?
Yes, the Lonza Group AG (LONN) stock pays dividends to shareholders. As of September 15, 2025, the dividend rate is €4.28155 and the yield is 0.36%. Lonza Group AG has a payout ratio of 38.2% on a trailing twelve-month basis.
When is the next Lonza Group AG dividend payment date?
The next Lonza Group AG (LONN) dividend payment date is unconfirmed.
What is the beta indicator for Lonza Group AG?
Lonza Group AG (LONN) has a beta rating of 0.8. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.